No Data
No Data
SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 ann
SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 annual report and 2024 quarterly report, and the profit side achieved rapid growth; 2) sales expenses continued to be optimized, and profitability improved; 3) Continued improvement of the product matrix, and innovative pharmaceutical devices are expected to be realized. (Mainichi Keizai Shimbun)
Baiyang Pharmaceutical (301015): Committed to building a “brand highway”, profitability is expected to continue to increase
Incident: The company released its annual report for the year 20223 and the quarterly report for 2024. In 2023, it achieved operating income of 7.564 billion yuan (yoy +0.72%) and net profit to mother of 656 million yuan (yoy +30%), deducted
China Galaxy released a research report on April 23 stating that Baiyang Pharmaceutical (301015.SZ) was given a recommended rating. The main reasons for the rating include: 1) focus on core brand operations, and the pharmaceutical business continues to sh
China Galaxy released a research report on April 23 stating that Baiyang Pharmaceutical (301015.SZ) was given a recommended rating. The main reasons for the rating include: 1) focus on core brand operations, and the pharmaceutical business continues to shrink; 2) the Q1 revenue side declined slightly, and the profit side maintained rapid growth; 3) entering the development of cutting-edge domestic innovative pharmaceutical devices and gradually establishing its own innovation incubation platform. (Mainichi Keizai Shimbun)
Baiyang Pharmaceutical (301015.SZ): Plans to jointly invest in partnerships with professional investment institutions
Gelonghui, April 23 | Baiyang Pharmaceutical (301015.SZ) announced that the company collaborates with AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., and Tianjin Jiashan Industrial Development Investment Co., Ltd. Invested in the establishment of AstraZeneca CICC
Baiyang Pharmaceutical (301015.SZ) plans to invest 50 million yuan in AstraZeneca CICC Qingdao Healthcare Venture Capital Fund to invest in the healthcare sector
Baiyang Pharmaceutical (301015.SZ) announced that the company, AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC...
A-share pharmaceutical stocks declined, and many stocks such as Zhifei Biotech fell by more than 10%
Gelonghui, April 23 | Zhifei Biotech, Baiyang Pharmaceutical, Tuoxin Pharmaceutical, and Baicheng Pharmaceutical all fell by more than 10%, while Anke Biotech and Tebao Biotech fell more than 8%.
No Data